siRNA Design
From first discoveries in the 1990s to FDA approval in 2018, siRNA has shown huge promise as the next major drug modality. All the insights you will ever need to design effective siRNAs — from the science to practical considerations.
How siRNAs silence genes through the RISC complex and AGO2.
From the 1990 petunia experiment to FDA-approved therapeutics.
The evolution of stabilizing modifications, from endo-light to ESC+.
Ui-Tei rules for choosing an effective guide strand.
Getting siRNA into cells: conjugates and lipid nanoparticles.
Targeting ligands — GalNAc, C16 and antibody conjugates.
The biotechs building the RNAi pipeline.
Programs in development across the industry.
Indications targeted by siRNA therapeutics.
Market and industry outlook for the modality.
FDA-approved siRNA therapeutics.
Browse the RefSeq transcript catalog.